| Craig A. Collard |
Craig A. Collard was the founder of Cornerstone BioPharma, Inc. (founded in 2004) where he served as Chief Financial Officer from 2010 to 2011. He was also the founder of Cornerstone Therapeutics, Inc. (founded in 2008) where he held the title of Chairman & Chief Executive Officer from 2008 to 2014. Additionally, he founded Carolina Pharmaceuticals, Inc. in 2003 and served as President & Chief Executive Officer. Currently, Mr. Collard is the Chief Executive Officer & Director at Heron Therapeutics, Inc. since 2023. He is also a Director at BioMarck Pharmaceuticals Ltd., the Cystic Fibrosis Foundation, and the Hilltop Home Foundation. Since 2018, he has been the Lead Independent Director at Terrascend Corp. In his former roles, Mr. Collard served as President & Chief Executive Officer of Critical Therapeutics, Inc. He was the President, Chief Executive Officer & Director of Cornerstone Biopharma Holdings, Inc. from 2004 to 2008. From 2015 to 2021, he held the positions of President & Chief Executive Officer at Veloxis Pharmaceuticals A and Chief Executive Officer & Director at Veloxis Pharmaceuticals, Inc. He was the Chairman of Opiant Pharmaceuticals, Inc. from 2018 to 2023. He also served as an Independent Director at Sierra Oncology, Inc. from 2020 to 2022. Prior to that, he was the Director-National Accounts at DJ Pharma, Inc. from 1998 to 2002 and Vice President-Sales at Verum Pharmaceuticals, Inc. from 2002 to 2003. He also held a position at Dura Pharmaceuticals, Inc. as a Principal. Mr. Collard obtained his undergraduate degree from Southern Polytechnic State University. |
| David L. Szekeres |
David L. Szekeres occupies the position of Executive Chairman of Annai Systems, Inc., Chairman of GRI Bio, Inc. and Investor Relations Contract at Heron Therapeutics, Inc. He is also on the board of Association of Corporate Counsel, Sanford Burnham Prebys Medical Discovery Institute, Anochi Biopharma, Inc. and Animantis LLC.
He previously held the position of CFO, Secretary, CAO & General Counsel at Regulus Therapeutics, Inc., Attorney at O'Melveny & Myers LLP, Attorney at Latham & Watkins LLP, Chairman for Vallon Pharmaceuticals, Inc., Senior Associate at Robertson Stephens, Inc. and Head-Mergers & Acquisitions, Governance at Life Technologies Corp.
Mr. Szekeres received an undergraduate degree from the University of California, Irvine and a graduate degree from Duke University. |
| Adam Joseph Morgan |
Adam Joseph Morgan is currently the Chairman at Heron Therapeutics, Inc. and Alimera Sciences, Inc. He is also a Director at Health Outlook Corp. and a Partner at Avego Healthcare Capital LLC. In 2020, he became the Managing Member & Chief Investment Officer at Velan Capital Investment Management LP. Previously, he worked as a Principal at OneMain Finance Corp., a Research Associate at Cowen & Co. LLC, and an Analyst at Broadfin Capital LLC from 2018 to 2020. He also held positions as a Specialist-Retirement Plan at c5 Wealth Management LLC, a Senior Analyst at Iguana Healthcare Management LLC, and an Analyst at Pura Vida Investments LLC. Mr. Morgan completed his undergraduate degree at Bridgewater College and obtained an MBA from Radford University and The Curtis L. Carlson School of Management at the University of Minnesota. |
| Thomas B. Ottoboni |
Thomas B. Ottoboni is currently the Chief Scientific Officer & SVP-Pharmaceutical at Heron Therapeutics, Inc. He previously worked as the Director-Drug Delivery at Vitaphore Corp. from 1992 to 1994, Manager-Systems Development at InSite Vision, Inc. from 1994 to 1996, and Chief Operating Officer at POINT Biomedical Corp. from 1996 to 2008. He also served as the Vice President-Research & Development at Talima Therapeutics, Inc. from 2010 to 2011. Dr. Ottoboni obtained his undergraduate degree in 1981 and his doctorate degree in 1986 from the University of California, Berkeley. |
| Chris M. Storgard |
Chris M. Storgard is currently the Chief Medical Officer at Heron Therapeutics, Inc. He previously served as the Vice President-Clinical Research & Development at Ardea Biosciences, Inc. from 2013 to 2016 and as the Chief Medical Officer at Fate Therapeutics, Inc. from 2016 to 2018. Prior to that, he was a Member & Assistant Professor at Mayo Medical School from 2001 to 2004. Dr. Storgard holds a doctorate degree from the University of Saskatchewan. |
| Ira Duarte |
Ira Duarte is an Independent Director at Terrascend Corp. and EVP, Chief Financial & Accounting Officer at Heron Therapeutics, Inc. She previously worked as Director-Accounting & Financial Planning at Cornerstone Therapeutics, Inc. from 2009 to 2013. From 2018 to 2023, she served as Chief Financial Officer & VP-Controller at Veloxis Pharmaceuticals A. She also worked as a Senior Manager at Ernst & Young A. In addition, she was the Corporate Controller at BioDelivery Sciences International, Inc. from 2014 to 2016. Ms. Duarte completed her undergraduate degree at Florida Atlantic University. |
| Stephen R. Davis |
Stephen R. Davis is currently the Chief Executive Officer & Director at ACADIA Pharmaceuticals, Inc. He also holds the position of President, Chief Executive Officer & Director at the same company since 2015. Previously, he served as the President, CEO, CFO, COO & Secretary at Neurogen Corp. from 2008 to 2010. He was an Independent Director at Heron Therapeutics, Inc. from 2019 to 2023 and a Director at Heron Therapeutics, Inc. from 2012 to 2015. Additionally, he worked as an Executive Director at Trimeris, Inc. from 2007 to 2011. He has also served as an Independent Director at Bellicum Pharmaceuticals, Inc. from 2015 to 2024, Furiex Pharmaceuticals, Inc. from 2013 to 2014, and Synageva BioPharma Corp. from 2011 to 2015. Prior to his roles in the pharmaceutical industry, he worked as an Attorney-Corporate & Securities at Milbank LLP from 1990 to 1994. He also held the position of Chief Operating Officer & Executive Vice President at Ardea Biosciences, Inc. from 2010 to 2013. Mr. Davis completed his undergraduate degree at Southern Nazarene University in 1983 and obtained his graduate degree from Vanderbilt Law School in 1990. |
| Lisa Peraza |
Lisa Peraza holds the position of Chief Accounting Officer & Vice President at Heron Therapeutics, Inc.
In her past career she occupied the position of Executive Director & Controller at Ardea Biosciences, Inc.
Ms. Peraza received an undergraduate degree from the University of California, Santa Barbara. |
| William P. Forbes |
William P. Forbes founded Vivelix Pharmaceuticals, Ltd. in 2016, where he worked as President & Chief Executive Officer. Dr. Forbes also currently works at Beyond Air, Inc., as Independent Director from 2018, Beyond Air Ltd., as Director from 2018, Hallux, Inc., as Director from 2018, and Heron Therapeutics, Inc., as Chief Development Officer & Executive VP from 2023. Dr. Forbes also formerly worked at Salix Pharmaceuticals Ltd., as President-Medical, Research & Development in 2015, Metabasis Therapeutics, Inc., as VP, Clinical Development & Regulator Affairs in 2004, Otsuka America Pharmaceutical, Inc., as Group Leader, Glaxo, Inc., as Senior Clinical Research Scientist, and Trevi Therapeutics, Inc., as Chief Development Officer from 2021 to 2022. Dr. Forbes received his doctorate degree from Creighton University. |
| Christian Waage |
Christian Waage is an Independent Director at Heron Therapeutics, Inc. and the EVP-Technical Operations & Administration at Gossamer Bio, Inc. He previously worked as the Managing Director at Celgene Corp., Secretary, Vice President & General Counsel at Forcepoint LLC, Senior Vice President & General Counsel at Receptos LLC, Partner at DLA Piper LLP (United States), Secretary, Vice President & General Counsel at Ardea Biosciences, Inc., Principal at DLA Piper Rudnick Gray Cary US LLP, Secretary, General Counsel & Vice President at Websense LLC, and had various roles at Gray Cary Ware & Freidenrich LLP. He obtained his undergraduate degree from the University of California San Diego in 1989 and his graduate degree from the University of San Diego School of Law in 1997. Mr. Waage's current job(s) include being an Independent Director at Heron Therapeutics, Inc. and the EVP-Technical Operations & Administration at Gossamer Bio, Inc. |
| Craig A. Johnson |
Craig A. Johnson is currently the Lead Independent Director at Heron Therapeutics, Inc., the Director at Tetraphase Pharmaceuticals, Inc., and the Independent Director at Odonate, Inc. He previously served as the Independent Director at La Jolla Pharmaceutical Co., Mirati Therapeutics, Inc., Ardea Biosciences, Inc., DMK Pharmaceuticals Corp., Veracyte SD, Inc., PURE Bioscience, Inc., NovaDel Pharma, Inc., MitoKor, Inc., Vice President-Sales at Philip Morris USA, Inc., Vice President at Raptor Pharmaceuticals Corp., Chief Financial Officer & Vice President at TorreyPines Therapeutics, Inc., Chief Financial Officer & Vice President at TPTX, Inc., and Vice President at Horizon Pharmaceutical LLC. Mr. Johnson received his undergraduate degree from The University of Michigan-Dearborn in 1984. |
| Susan Rodriguez |
Susan Rodriguez is currently an Independent Director at Heron Therapeutics, Inc., a Director at Veradigm, Inc., a Director at The Santa Barbara Humane Society, a Director at Cuba Emprende Foundation, and the Chief Commercial Officer at Ardelyx, Inc. Her former positions include being the Chief Executive Officer at TOLMAR, Inc. and Tolmar Pharmaceuticals, Inc., Vice President-Global Marketing at Abbott Laboratories, Client Manager at Arbor Pharmaceuticals LLC, and Vice President & General Manager at TAP Pharmaceutical Products, Inc. Ms. Rodriguez received her undergraduate and graduate degrees from the University of Pennsylvania. |
| Sharmila Dissanaike |
Sharmila Dissanaike is currently the Chairman-Surgery Department at Texas Tech University Health Sciences Center. She is also serving as an Independent Director at Heron Therapeutics, Inc. and as a Director at Texas Medical Board. Additionally, she is a Member of the Southwestern Surgical Congress and the President of the American Burn Association. Previously, she worked as the Trauma Medical Director-John A. Griswold at University Medical Center from 2014 to 2017. Dr. Dissanaike holds a graduate degree from the University of Washington and a doctorate degree from The University of Sydney. |
